Skip to main content
Proton pump inhibitor use in clopidogrel-treated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.

Proton Pump Inhibitors and Clopidogrel

Proton pump inhibitor use in clopidogrel-treated post-percutaneous coronary intervention patients was not associated with an increased risk of all-cause death, nonfatal myocardial infarction, repeat revascularization, or major adverse cardiovascular events.